IBAB Ion Beam Applications SA

IBA launches the world’s first online proton therapy platform

IBA launches the world’s first online proton therapy platform

Campus, IBA’s new interactive platform dedicated to proton therapy, unveiled at ASTRO

Louvain-la-Neuve, Belgium, 20 October 2021 - IBA (Ion Beam Applications SA), the world leader in particle accelerator technology and the world’s leading provider of proton therapy solutions for the treatment of cancer, today announces the launch of the world’s first online platform dedicated to proton therapy. The new interactive platform called Campus was unveiled through a series of webinars on October 19-20, 2021. It will also be showcased at the American Society for Radiation Oncology (ASTRO) Annual Meeting, which IBA is attending from 24-27 October 2021.

Campus enables users to share proton therapy-related materials and resources, as well as discussion forums with other users, with the aim of helping clinicians and researchers in proton therapy to enhance and learn new skills for the benefit of patients. As part of the system, Campus visitors will also have access to IBA’s vast network of experts, all of whom have deep knowledge and experience in working with IBA’s state-of-the-art Proteus systems and who together have treated over 100,000 patients with proton therapy.

Prof Hans Langendijk, MD, PhD at UMC Groningen (The Netherlands) commented: “An online platform dedicated solely to proton therapy will allow users to access and utilize resources at the click of a button. I am excited to learn from IBA’s network of leading experts, as they share their latest findings, with the ultimate goal of improving not only the quality of patient treatment but also the general operations behind our proton therapy centers.”

Prof. Dr. James Metz,M.D., Chair of Penn Medicine Department of Radiation Oncology added: “Campus will be an invaluable tool to those working within the proton therapy field, particularly those starting out their careers in this dynamic area. Access to educational materials, focused events and support from IBA’s network of experienced operating centers will be key in allowing users to learn and assist in the advancement of this important technology.”

Prior to launch, Campus was presented to the proton therapy community, through a series of webinars held from 19-20 October. Demonstrations of the platform will also be made available at IBA’s booth during the ASTRO conference.

For more information or to join Campus, please visit: .

- END -

About IBA

IBA (Ion Beam Applications S.A.) is the world leader in particle accelerator technology. The company is the leading supplier of equipment and services in the field of proton therapy, considered to be the most advanced form of radiation therapy available today. IBA is also a leading player in the fields of industrial sterilization, radiopharmaceuticals and dosimetry. The company, based in Louvain-la-Neuve, Belgium, employs approximately 1,500 people worldwide. IBA is a certified B Corporation (B Corp) meeting the highest standards of verified social and environmental performance.

IBA is listed on the pan-European stock exchange EURONEXT (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB).

More information can be found at:

For further information, please contact:

IBA

Aymeric Harmant

Proton Therapy Global Marketing Director



Olivier Lechien

Corporate Communication Director



For media and investor enquiries:

Consilium Strategic Communications

Amber Fennell, Angela Gray, Lucy Featherstone

+44 (0) 20 3709 5700

Attachment



EN
20/10/2021

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Ion Beam Applications SA

 PRESS RELEASE

IBA – Regulated information

IBA – Regulated information                                                                                                                   November 7th, 2025 Publication made under article 15 of the law of May 2, 2007 relating to the disclosure of major holdings in issuers whose shares are admitted to trading on a regulated market and containing various provisions (Belgian Gazette 12.VI.2007) (hereinafter, the “Law”). Under this provision:  « [...] the issuer publishes the total capital, the total number of securities conferring the right to vote and voting rights, as well as, by cate...

 PRESS RELEASE

IBA – Information Réglementée

IBA – Information Réglementée 7 novembre 2025 Publication effectuée en vertu de l’article 15 de la loi du 2 mai 2007 relative à la publicité des participations importantes dans des émetteurs dont les actions sont admises à la négociation sur un marché réglementé et portant des dispositions diverses (M.B. 12.VI.2007) (ci-après, la « Loi »). En vertu de cette disposition : « [...] l'émetteur publie le total du capital, le nombre total de titres conférant le droit de vote et de droits de vote, ainsi que, par catégorie, le nombre de titres conférant le droit de vote et de droits de vote, au ...

 PRESS RELEASE

IBA integrates Artificial Intelligence Quality Assurance into dosimetr...

IBA integrates Artificial Intelligence Quality Assurance into dosimetry solutions through the acquisition of PhantomX GmbH Dosimetry portfolio strengthened with Medical Imaging QA and AI validation  Louvain-la-Neuve, Belgium, 03 November 2025 - IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology and a world-leading provider of quality assurance (QA) solutions, today announces the acquisition of PhantomX GmbH, expanding IBA’s portfolio in healthcare diagnostics and therapeutic systems enabling artificial intelligence (AI) quality assurance. Found...

 PRESS RELEASE

IBA intègre l’assurance qualité de l’intelligence artificielle dans se...

IBA intègre l’assurance qualité de l’intelligence artificielle dans ses solutions de dosimétrie grâce à l'acquisition de PhantomX GmbH Renforcement du portefeuille de Dosimetry avec l'assurance qualité en imagerie médicale et la validation par IA Louvain-la-Neuve, Belgique, le 3 novembre 2025 – IBA (Ion Beam Applications S.A., EURONEXT), le leader mondial des technologies d’accélération de particules et l'un des principaux fournisseurs de solutions de dosimétrie et d'assurance qualité en radiothérapie et en imagerie médicale (QA), annonce aujourd'hui l'acquisition de PhantomX GmbH, élargis...

 PRESS RELEASE

IBA opens the world of science and technology to secondary school girl...

IBA opens the world of science and technology to secondary school girls Its Innovat’her event brought together female students to explore careers in STEM Louvain-la-Neuve, Belgium, October 17, 2025 - IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology, hosted the Innovat’her event yesterday, aimed at girls in their fifth and sixth years of secondary school. The goal was to introduce them to scientific and technical careers, which remain underrepresented in the academic choices of female students. The event welcomed 25 students, invited by IBA co...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch